📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-28 14:47
79 analysed today
FollowTelegram
79
Today
151,523
All-time analysed
43,415
Positive
6,735
Negative
92,557
Neutral
8,748
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Zenotech Reports Q1 FY27 Net Loss of ₹0.46 Cr as Expenses Outpace 11% Revenue Growth
Zenotech Laboratories reported a net loss of ₹0.46 crore for the quarter ended June 30, 2026, compared to a profit of ₹0.99 crore in the same period last year. While revenue from operations grew 11.1% YoY to ₹9.60 crore, total expenses surged 30.1% YoY to ₹11.65 crore, primarily due to higher employee and other operating costs. The company continues to rely on rental income of ₹1.02 crore from leasing its biotech facility to Sun Pharmaceutical Industries. The 37th Annual General Meeting is scheduled for September 25, 2026.
Confidence: HIGH
What changedThe company swung from a net profit in Q1 FY26 to a net loss in Q1 FY27, despite a modest increase in top-line revenue.
Why it mattersFor a small-cap company with a ₹268 Cr market cap, the inability to maintain profitability despite revenue growth suggests rising operational inefficiencies or cost pressures that could impact its thin net worth.
Revenue from Operations (Q1 FY27): ₹9.60 CrNet Loss (Q1 FY27): ₹0.46 CrYoY Revenue Growth: 11.1%YoY Expense Growth: 30.1%Q1 Revenue vs TTM Revenue: 21.8%
📅 Short termThe stock may face downward pressure in the coming weeks as the market reacts to the YoY swing from profit to loss.
📈 Long termThe company's long-term outlook remains constrained by stagnant revenue growth and a high dependence on rental income from a single major pharmaceutical player.
⚠ Risk flags
- Rising employee benefit expenses
- Inconsistent profitability
- High reliance on rental income from Sun Pharma
Key Highlights
Revenue from operations increased to ₹9.60 crore from ₹8.64 crore in Q1 FY26.
Total expenses rose significantly to ₹11.65 crore, up from ₹8.95 crore in the year-ago quarter.
Reported a net loss of ₹0.46 crore, a sharp decline from the ₹0.99 crore profit in Q1 FY26.
Other operating income remained steady at ₹1.02 crore, derived from leasing facilities to Sun Pharma.
Employee benefit expenses increased by 39% YoY to ₹4.92 crore.
👀 What to Watch
Monitor the company's ability to contain operating costs, particularly employee expenses, which are currently eroding revenue gains. Investors should look for updates on the utilization of the biotech facility during the AGM on September 25, 2026.
Zenotech Q1 Results: Revenue Up 11% YoY to ₹9.60 Cr, Swings to Net Loss of ₹0.46 Cr
Zenotech Laboratories reported a marginal 11.1% YoY increase in revenue from operations to ₹9.60 crore for Q1 FY27. Despite the revenue growth, the company posted a net loss of ₹0.46 crore, a sharp reversal from the ₹0.99 crore profit recorded in the same quarter last year. This downturn was driven by a 30% surge in total expenses, particularly employee benefit costs which rose 39% YoY. The company continues to rely on rental income of ₹1.02 crore from Sun Pharma for its biotech facility to support its top line.
Confidence: HIGH
What changedThe company has transitioned from a profitable position in Q1 last year to a loss-making one this quarter, despite a modest increase in revenue.
Why it mattersFor a small-cap company with a market cap of ₹268 crore and a history of marginal profitability, the 30% spike in expenses is a significant concern for bottom-line stability.
Revenue from Operations (Q1): ₹9.60 CrNet Loss (Q1): ₹0.46 CrYoY Expense Growth: 30.1%Rental Income from Sun Pharma: ₹1.02 CrRevenue vs TTM Revenue: 21.8%
📅 Short termThe stock may face downward pressure in the coming weeks as the market reacts to the swing from profit to loss and the compression of operating margins.
📈 Long termThe company's structural reliance on rental income from Sun Pharma and its inability to scale core pharmaceutical operations profitably remain long-term challenges.
⚠ Risk flags
- Rising employee benefit costs
- Operating expenses growing faster than revenue
- Concentration risk with Sun Pharma for rental income
Key Highlights
Revenue from operations increased 11.1% YoY to ₹9.60 crore from ₹8.64 crore.
Total expenses surged 30.1% YoY to ₹11.65 crore, outpacing revenue growth.
Employee benefit expenses rose significantly to ₹4.92 crore compared to ₹3.54 crore in the year-ago period.
Reported a net loss of ₹0.46 crore for the quarter versus a net profit of ₹0.99 crore YoY.
Other operating income of ₹1.02 crore was generated from leasing facilities to Sun Pharmaceutical Industries.
👀 What to Watch
Investors should monitor the company's ability to contain rising operating costs, especially employee and 'other' expenses, which are currently eroding margins. The upcoming Annual General Meeting on September 25, 2026, may provide more clarity on the long-term utilization of its Hyderabad facility.
